Articles
Study Results

Retatrutide and Alcohol: What the Research Shows About Drinking

No official rule covers alcohol and retatrutide. Five concrete effects from the research: a slower early rise, possibly higher blood alcohol, less craving, common nausea and two known alcohol risks.

Written By
retaweightloss.com
Updated on
17 Nov 2026
Time to read
5 min read
Category
Study Results
Retatrutide and alcohol: what the research shows

Retatrutide and Alcohol: What the Research Shows About Drinking

No official rule covers alcohol and retatrutide. Five concrete effects from the research: a slower early rise, possibly higher blood alcohol, less craving, common nausea and two known alcohol risks.

By
RetaWeightLoss.com
Created on:
15 Jul 2026
Updated on:
17 Nov 2026
Share this post

Can People Drink Alcohol on Retatrutide? The Short Answer

There is no official rule either way. Retatrutide is an investigational medicine with no approved label, so there is no alcohol warning and no alcohol permission. The published TRIUMPH-1 paper does not discuss alcohol, and its supplementary appendix mentions it only as an example in a general exclusion rule: people could be kept out of the trial if, in the investigator's opinion, a condition such as alcohol abuse might put their safety at risk. We found no published study in people that tested retatrutide together with alcohol.

Research on retatrutide in rats and on similar drugs in people and mice does point to five concrete effects:

  • Alcohol may feel weaker at first. In a 2025 pilot study, people taking GLP-1 medicines had a slower rise in breath alcohol in the first 20 minutes and lower overall alcohol exposure than people not taking them.
  • Blood alcohol may end up higher than expected. In mice, semaglutide lowered a liver enzyme that breaks down alcohol, and blood alcohol was higher after the same dose. The researchers warned that, if this holds in humans, an amount that would not normally put someone over the legal limit could do so.
  • The urge to drink may fall. In a 2025 randomized trial in adults with alcohol use disorder, low-dose semaglutide reduced craving and how much people drank in a laboratory session. In rats, retatrutide blunted how strongly the animals recognized alcohol's effects at the highest dose tested.
  • Stomach side effects are already common. In TRIUMPH-1, nausea was reported by 42.4% of people on the highest dose, 12 mg, against 14.8% on placebo, and vomiting by 25.3% against 4.8%, mostly while the dose was being increased.
  • Two risks are well established for alcohol itself. Alcohol can cause low blood sugar, mainly in people who take insulin or sulfonylureas, and heavy drinking is one of the most common causes of pancreatitis.

Most of this evidence is small, in animals or about other drugs, so none of it can say what drinking on retatrutide would do to a given person. The sections below give the details of each study.

The Only Published Study of Retatrutide and Alcohol

In 2025, researchers published a study in Psychopharmacology (Windram et al.) titled "Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats." Rats were trained to recognize how alcohol feels, then given one of the three drugs before alcohol.

All three drugs reduced how strongly the rats recognized alcohol's effects. For retatrutide, the reduction was significant only at the highest dose tested, with no effect on how actively the rats responded, which suggests the result was not simply from the animals being less active. The authors note that GLP-1 drugs slow stomach emptying, which could change how alcohol is absorbed, and say a critical next step is to determine how these drugs change the absorption of alcohol.

Retatrutide was tested only as single doses in rats. It does not show how retatrutide affects drinking, intoxication or safety in people.

How GLP-1 Drugs May Change How Alcohol Is Absorbed

A small pilot study published in Scientific Reports in October 2025 (Quddos et al.) gave a measured amount of alcohol to 20 adults with obesity. Ten were already taking a GLP-1 medicine, mostly semaglutide, and ten were not.

In the GLP-1 group, breath alcohol rose more slowly in the first 20 minutes, and their ratings of how intoxicated they felt also rose more slowly, although differences at individual time points were not statistically significant. Overall exposure, measured as the area under the breath alcohol curve, was lower. From 35 to 60 minutes, breath alcohol in the two groups was not significantly different.

The researchers suggest slower stomach emptying as one explanation, because alcohol is absorbed mainly in the upper intestine, but they did not measure stomach emptying. The study was not randomized, the sample was small, and no one in it was taking retatrutide.

Higher Blood Alcohol in Mice: The Yale Study

A September 2025 study from Yale School of Medicine, published in npj Metabolic Health and Disease (Zahrawi et al.), looked at the liver. In mice, semaglutide lowered levels of Cyp2e1, a liver enzyme that helps break down alcohol, and did so even in mice that were not drinking. As the authors expected from that change, blood alcohol levels were higher after a dose of alcohol in mice given the drug.

Because Cyp2e1 turns alcohol into acetaldehyde, a compound that damages the liver, the authors suggest the drug could reduce alcohol-related liver injury while raising blood alcohol. The study's senior author, Wajahat Mehal, said: "If these results are reproduced in humans, people using GLP-1 receptor agonists might be drinking an amount of alcohol that does not normally put them above the legal blood alcohol level, but because they are taking this drug, it does."

These are mouse results with semaglutide. They have not been confirmed in people, and retatrutide was not tested.

Can Retatrutide Reduce Alcohol Cravings?

No published study has tested this in people, as far as we found. The closest human evidence is for semaglutide. A randomized trial published in JAMA Psychiatry in 2025 (Hendershot et al.) enrolled 48 adults with alcohol use disorder for nine weeks of low-dose semaglutide or placebo.

Semaglutide reduced the amount of alcohol people drank in a laboratory drinking session, as well as their weekly craving and the number of drinks on days they drank. It did not significantly change average drinks per day. The authors called the findings initial evidence that justifies larger trials.

Whether retatrutide has a similar effect in people is unknown. The rat study above is the only published research found that tested it with alcohol, and none of the retatrutide obesity trials listed on Lilly's medical information site studies alcohol use.

Alcohol, Diabetes Medicines and Low Blood Sugar

Alcohol can lower blood sugar. The American Diabetes Association explains that the liver will prioritize breaking down alcohol over keeping blood glucose up, and that the biggest concern is low blood sugar when drinking is combined with insulin or sulfonylureas. It notes that low blood sugar can occur hours after the last drink.

Separately, the US label for tirzepatide (Zepbound), an approved GLP-1-based medicine, warns that the risk of low blood sugar rises when it is used with insulin or a sulfonylurea. How retatrutide, alcohol and these medicines would interact together has not been studied. What is known about retatrutide and blood sugar is covered in retatrutide for type 2 diabetes.

Nausea, Pancreatitis and Alcohol

Stomach and bowel side effects were the most common side effects of retatrutide in TRIUMPH-1. Through 80 weeks of treatment and follow-up, nausea was reported by 42.4% of people on 12 mg and 14.8% on placebo, and vomiting by 25.3% and 4.8%. The paper says these events were mostly mild or moderate and occurred mostly while the dose was being increased. No published study has looked at whether alcohol makes them worse on retatrutide.

Tirzepatide's US label carries a warning about acute pancreatitis, and heavy alcohol use is one of its common causes, according to the US National Institute of Diabetes and Digestive and Kidney Diseases. In TRIUMPH-1 there were 8 confirmed cases of pancreatitis among 1,749 people on retatrutide and 2 among 586 on placebo; the authors say these small numbers "do not permit conclusions regarding a treatment effect." The trial data on pancreatitis are covered in retatrutide and pancreatitis.

What Is Still Unknown

  • How alcohol is absorbed and cleared in people taking retatrutide.
  • Whether retatrutide's glucagon component changes the effects of alcohol on blood sugar or the liver. What is known about retatrutide and liver fat is covered in retatrutide and fatty liver.
  • Whether retatrutide changes how much people want to drink.
  • What official guidance on alcohol would say if retatrutide were approved.

Retatrutide is not approved. Lilly says it is not on the market and that no one can legally sell it for human use, and it warns that illicit products "may contain unknown ingredients, harmful contaminants and impurities." The research above does not describe such products. Longer-term safety data are covered in retatrutide long-term safety.

Retatrutide and Alcohol in Summary

Retatrutide has no official guidance on alcohol because it is not approved, and no published study has tested it with alcohol in people, as far as we found. The only study that included it was in rats, where it reduced how strongly the animals recognized alcohol's effects at the highest dose. Studies of older GLP-1 medicines suggest they can slow the early rise in breath alcohol, raise blood alcohol in mice by lowering a liver enzyme, and reduce craving in people with alcohol use disorder, but none of these findings has been confirmed for retatrutide.

Sources

  • Windram M, Lovelock DF, Carew JM, et al. Semaglutide, tirzepatide, and retatrutide attenuate the interoceptive effects of alcohol in male and female rats. Psychopharmacology. Published online July 23, 2025. DOI: 10.1007/s00213-025-06854-3
  • Quddos F, et al. A preliminary study of the physiological and perceptual effects of GLP-1 receptor agonists during alcohol consumption in people with obesity. Scientific Reports. October 15, 2025. DOI: 10.1038/s41598-025-17927-w
  • Zahrawi F, Suyavaran A, Banini BA, Mehal WZ. GLP-1 receptor agonism results in reduction in hepatic ethanol metabolism. npj Metabolic Health and Disease. September 18, 2025. DOI: 10.1038/s44324-025-00077-y
  • Yale School of Medicine. GLP-1 receptor agonists protect the liver during alcohol consumption. September 18, 2025.
  • Hendershot CS, Bremmer MP, Paladino MB, et al. Once-Weekly Semaglutide in Adults With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry. 2025;82(4):395–405.
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
  • Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Supplementary Appendix, exclusion criteria. N Engl J Med. 2026.
  • American Diabetes Association. Alcohol and diabetes.
  • Eli Lilly. US prescribing information for tirzepatide for weight reduction, sections 5.5 and 5.7.
  • National Institute of Diabetes and Digestive and Kidney Diseases. Symptoms and causes of pancreatitis.
  • Eli Lilly. What to know about retatrutide.

Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. Nothing here is a recommendation about alcohol use or any medication.

Frequently asked questions

Can people drink alcohol on retatrutide?

There is no official rule either way, because retatrutide has no approved label. Research on similar drugs suggests alcohol may feel weaker at first while blood alcohol may end up higher than expected, and the urge to drink may fall. Nausea and vomiting were already common on retatrutide in its main trial.

What happens when alcohol is combined with retatrutide?

No published study has tested this in people, as far as we found. In a small pilot study, people taking older GLP-1 medicines had a slower early rise in breath alcohol and in how intoxicated they felt. In mice, semaglutide raised blood alcohol levels by lowering a liver enzyme that breaks down alcohol. Neither study included retatrutide.

Does retatrutide reduce alcohol cravings?

It is not known in people. In a 2025 rat study, retatrutide reduced how strongly rats recognized alcohol's effects, but only at the highest dose tested. In a 2025 randomized trial in adults with alcohol use disorder, low-dose semaglutide reduced craving and some drinking measures. No published study has tested retatrutide this way in people.

Does drinking alcohol on retatrutide cause nausea?

No published study has looked at this, as far as we found. Nausea and vomiting were the most common side effects of retatrutide in its main Phase 3 trial, mostly while the dose was being increased, but the trial did not study alcohol. Whether drinking worsens these effects on retatrutide is unknown.

Newsletter

Stay Updated on New Articles & Research

Get notified when we publish new articles, research, and insights on obesity and weight loss.
You're subscribed!
You'll get new coverage as it's published.
Oops! Something went wrong while submitting the form.